Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma

PURPOSE: This phase I trial was performed to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), preliminary efficacy, and pharmacokinetics (PK) of LY01610, a novel liposome-encapsulated irinotecan, in patients with advanced esophageal squamous cell carcinoma (ESCC). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yun, Zhang, Bo, Xu, Jianping, Wang, Xingyuan, Tang, Jialin, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143070/
https://www.ncbi.nlm.nih.gov/pubmed/34031756
http://dx.doi.org/10.1007/s00280-021-04294-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143070/
https://www.ncbi.nlm.nih.gov/pubmed/34031756
http://dx.doi.org/10.1007/s00280-021-04294-2

Ejemplares similares